

## FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

<b>Patient Name:</b>	SAMPLE, JANET	<b>Cytogenetics Number:</b>	16-XXXX
<b>Date of Birth:</b>	03/16/1984	<b>Customer Specimen ID:</b>	XX-XXXX
<b>Sex:</b>	Female	<b>Collection Date:</b>	02/10/2016
<b>Specimen Type:</b>	AMNIOTIC FLUID	<b>Received Date:</b>	02/11/2016
<b>Physician:</b>	JANE DOCTOR, M.D.	<b>Requested Date:</b>	02/11/2016
<b>Clinical Data:</b>	INCREASED RISK FOR TRISOMY 21	<b>Reported Date:</b>	02/18/2016

**Results:** **Abnormal FISH result for D21S259 (Abbott)**

INTERPRETATION: Abnormal result for the Aneuvysion FISH panel. This pattern is consistent with a female with trisomy 21.


A preliminary report was faxed on 2/12/15.

### FISH ANALYSIS

Probe	Chromosome Target	Result
<b>D21S259 (Abbott)</b>	<b>TRISOMY 21</b>	<b>Positive</b>
RB1 (Abbott)	TRISOMY 13	Negative
D18Z1 (Abbott)	TRISOMY 18	Negative
DXZ1 (Abbott)	SEX CHROMOSOME ANEUPLOIDY	Negative
DYZ3 (Abbott)	SEX CHROMOSOME ANEUPLOIDY	Negative

### FISH INTERPRETATION

- 1 Three signals for chromosome 21 were seen in 47 out of 50 (94.00%) interphase nuclei examined.**
- 2 Two signals for chromosome 13 were seen in 48 out of 50 (96.00%) interphase nuclei examined.
- 3 Two signals for chromosome 18 were seen in 50 out of 50 (100.00%) interphase nuclei examined
- 4 Two signals for chromosome X were seen in 49 out of 50 (98.00%) interphase nuclei examined.
- 5 No signals for the Y chromosome were seen in 50 out of 50 (100.00%) interphase nuclei examined.



JANE DOCTOR, M.D.  
SAMPLE HOSPITAL  
1234 MEDICAL CENTER DRIVE  
CITY, ST 00000



## FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

<b>Patient Name:</b> SAMPLE, JANET	<b>Cytogenetics Number:</b> 16-XXXX
<b>Date of Birth:</b> 03/16/1984	<b>Customer Specimen ID:</b> XX-XXXX

CPT Codes: 88377x2

ISCN Diagnosis 13q14(RB1x2)[48/50], 18p11.1-q11.1(D18Z1x2)[50/50], 21q22.13-q22.2(D21S259x3,D21S341x3,D21S342x3)[47/50], Xp11.1-q11.1(DXZ1x2)[49/50], Yp11.1-q11.1(DYZ3x0)[50/50]

Note: The Aneuvysion Assay Kit has been cleared by the FDA for use in conjunction with fetal karyotype analysis that provides a rapid method for detection of trisomy 13, 18, 21 and sex chromosome aneuploidies. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Reviewed By:

\_\_\_\_\_  
KATHLEEN LEPPIG, M.D.

JANE DOCTOR, M.D.  
SAMPLE HOSPITAL  
1234 MEDICAL CENTER DRIVE  
CITY, ST 00000

